Kairos Pharma (KAPA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$1.4M

Net income growth (year over year)

+2.39%

Net margin

—

Return on equity

−113.96%

EPS (trailing twelve months)

−$1.12

Book value per share

$1.37

P/E (trailing twelve months)

—

Price to book

0.67

Debt to assets

5.95%

Payout ratio

—

Dividend yield

—

Company profile

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.

• How do I buy stock in Kairos Pharma (KAPA)?

  KAPA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.